InMed Pharmaceuticals Inc. Common Shares (INM) Stock Price
INMStock
$1.32−36.54%52W
Market Cap$7.25M
P/E—
PEG Ratio—
Div yield—
Beta1.05
INM Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)74.79%
Price vs S&P 500 (4W)-3.02%
VGM Score41.63
INM Analyst Recommendations
Nov 2022
Dec 2022
Jan 2023
Feb 2023
2.25
2.25
2.25
2.25
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
INMInMed Pharmaceuticals Inc. Common Shares | C | D | B | 2.2x | -32.8% | 35.9% | — | $1.32 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About InMed Pharmaceuticals Inc. Common Shares
InMed Pharmaceuticals is a clinical-stage Canadian biopharmaceutical company developing small molecule therapies for rare diseases, with a pipeline including candidates for epidermolysis bullosa, glaucoma, and Alzheimer's disease. The company also operates BayMedica, a commercial segment producing rare cannabinoids for the health and wellness market.